OA04.01 What is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?

B. Gutierres; B. Dourado; A. Alves; P. Aguiar; C. Barreto; G. Lopes; A. Del Giglio

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >OA04.01 What is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?

【24h】

OA04.01 What is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?

机译：OA04.01治疗晚期非小细胞肺癌的有力证据的成本是多少？

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共1页
作者
B. Gutierres; B. Dourado; A. Alves; P. Aguiar; C. Barreto; G. Lopes; A. Del Giglio;
展开▼
作者单位

Universidade Paulista;

Universidade Paulista;

Universidade Paulista;

Faculdade de Medicina Do Abc;

Beneficencia Portuguesa de S?o Paulo;

Global Oncology Sylvester Comprehensive Cancer Center at the University of Miami;

Faculdade de Medicina Do Abc;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. OA04.01 What is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer? [J] . B. Gutierres, B. Dourado, A. Alves, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：OA04.01治疗晚期非小细胞肺癌的有力证据的成本是多少？
2. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis [J] . NelsonR.E., StenehjemD., AkerleyW. Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2013,第3期

机译：接受VeriStrat指导的个体化治疗与标准治疗策略对晚期非小细胞肺癌二线治疗患者的比较：成本-效用分析
3. 731?Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis [J] . Jonathan Kish, Dhruv Chopra, Djibril Liassou, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：731？优先线（1L）治疗先进的非小细胞肺癌（ANSCLC）的费用：真实世界声明分析
4. Chemotherapy in Advanced Stage Non-small Cell Lung Cancer - Have We Got the Evidence [C] . R.P. Perng, Y.M. Chen Asian Pacific Society of Respirology . 2003

机译：化疗在晚期非小细胞肺癌 - 我们有证据吗？
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. Treatment Patterns Clinical Outcomes and Healthcare Costs of Advanced Non-Small Cell Lung Cancer: A Real-World Evaluation in Italy [O] . Matteo Franchi, Diego Cortinovis, Giovanni Corrao 2021

机译：治疗模式晚期非小细胞肺癌的临床结果和医疗成本：意大利的真实评价
7. PCN33 Indirect Analysis of the Efficacy and Safety of Pemetrexed/Cisplatin Compared With Bevacizumab/Gemcitabine/Cisplatin as First-Line Treatment for Advanced, Non-Squamous Non-Small Cell Lung Cancer and Associated Treatment Costs in the Private Mexican Health Care System [O] . Ramirez Gamez J., Cruz Cadena A., Davey P., 2012

机译：培美曲塞/顺铂与贝伐单抗/吉西他滨/顺铂相比作为晚期，非鳞状非小细胞肺癌一线治疗的有效性和安全性的PCN33间接分析及墨西哥私人医疗保健系统中的相关治疗费用

OA04.01 What is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?

著录项

相似文献

相关主题

期刊订阅